RPS Marks Growth with Appointment of Industry Experts to Board of Directors

Share Article

Stephen La Neve and Charles Saldarini have been appointed to the RPS Board of Directors.

Rapid Pathogen Screening, Inc. (RPS®), an emerging leader in point-of-care (POC) diagnostic testing, today announced Stephen La Neve and Charles Saldarini have been appointed to the company’s Board of Directors. Mr. La Neve and Mr. Saldarini bring extensive experience in POC diagnostics and biopharmaceutical services to RPS and will expand the breadth and capabilities of the RPS Board to help guide the company’s continued worldwide strategic growth. RPS’s growth and success is marked by its achievement of several important milestones, including clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver designation by the U.S. Food and Drug Administration (FDA) for its flagship product, AdenoPlus®.

“The robust industry experience Steve and Chuck bring to the RPS team will accelerate RPS’s growth as a leader in global POC diagnostics,” said Robert Sambursky, MD, chief executive officer, president, and chairman of RPS. “We look forward to the critical contributions and active involvement of the new members of the RPS Board of Directors.”

With more than 30 years of global healthcare experience, Mr. La Neve brings leadership to the RPS Board as the co-founder and CEO of SkelRegen, a leader in small molecule musculoskeletal tissue regeneration. He has held leadership roles in the device and diagnostic industry, most recently as president of Becton Dickinson’s Pre-Analytical Systems business, president of Medtronic’s $3.5 billion Spine and Biologics business and its Japanese business unit, the company’s second largest country business unit. Mr. La Neve also served in a number of commercial leadership positions at Roche Diagnostics, E Merck Diagnostic Systems, and in Becton Dickinson’s Point of Care Division. In these positions, La Neve has led sales, marketing, strategic planning, and project management efforts both in the U.S. and internationally.

As a recognized expert in biopharmaceutical services, Mr. Saldarini is an acknowledged leader and innovator across all phases of business growth and turnaround. He is the founder and CEO of The Charles T. Saldarini Group, an independent consulting organization providing strategic assessments for private equity investment, commercial product development, and growth opportunities for life science companies. Most recently, Mr. Saldarini served as head of Global Business Development for Octagon Clinical Research Solutions and as a member of the deal team that led the organization’s sale to Accenture. Previously, he was CEO and vice chairman of Sentrx, where he successfully led a complete turnaround resulting in measurably higher quality, improved competitive position, and sustained profitability. He also led PDI, Inc., as CEO and vice chairman from its inception through peak service revenues of $365 million.

About RPS
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS®) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to support the rapid diagnosis of patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being developed to help detect the body’s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit RPSdetectors.com.

# # #

For additional information, contact:
Laura Lovejoy, 941.928.9025, laura(at)saranova(dot)net

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Lovejoy
Visit website